Michael Conick Hanley
Directeur des opérations chez ALTO NEUROSCIENCE, INC.
Fortune : 50 608 $ au 31/05/2024
Postes actifs de Michael Conick Hanley
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ALTO NEUROSCIENCE, INC. | Directeur des opérations | 20/05/2024 | - |
Historique de carrière de Michael Conick Hanley
Anciens postes connus de Michael Conick Hanley
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| SPYRE THERAPEUTICS, INC. | Corporate Officer/Principal | 04/11/2019 | 14/04/2023 |
Esteve Pharmaceuticals S.A.
 Esteve Pharmaceuticals S.A. Pharmaceuticals: OtherHealth Technology Esteve Pharmaceuticals S.A. operates as a global pharmaceutical company. It provides Ophthalmology and other Pathologies therapies. The company is headquartered in Barcelona, Spain. | Corporate Officer/Principal | 01/04/2018 | 01/09/2019 |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Sales & Marketing | 01/07/2015 | 01/06/2017 |
Formation de Michael Conick Hanley
| Kellogg School of Management | Masters Business Admin |
| Notre Dame University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 4 |
| Liban | 2 |
| Espagne | 2 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Masters Business Admin | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| ALTO NEUROSCIENCE, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Esteve Pharmaceuticals S.A.
Esteve Pharmaceuticals S.A. Pharmaceuticals: OtherHealth Technology Esteve Pharmaceuticals S.A. operates as a global pharmaceutical company. It provides Ophthalmology and other Pathologies therapies. The company is headquartered in Barcelona, Spain. | Health Technology |
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
- Bourse
- Insiders
- Michael Conick Hanley
- Expérience
